NDA 050299 · Chartwell Molecules
Nilstat
Nystatin · Oral · Polyene Antifungal
Last checked: Nov 19, 2026Latest source record: Sep 23, 1999 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1971
Apr 14, 1971
Approved uses
1
Original approval plus efficacy supplements
Registered trials
56
16 Phase 3, 1 recruiting
FAERS reports
26,454
20,553 serious, 3,637 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 5, 2026.
INDICATIONS AND USAGE Nystatin oral suspension is indicated for the treatment of infections of the oral cavity caused by Candida albicans .
Therapeutic areas: Cardiovascular and metabolic · Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 14, 1971 Original approval
1 products under this application
- NILSTAT · NYSTATIN 100,000 UNITS/ML · SUSPENSION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Nystatin" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Ecological Effects of Decolonisation Strategies in Intensive CarePivotal-lookingCompleted
MJM BontenAcademic, hospital or other
NCT02208154 · 8,665 participants · Start Dec 1, 2013 · Primary completion Oct 27, 2017
Drug: Chlorhexidine oral care (CHX-Oro); Selective oropharyngeal decontamination (SOD) and 1 more · For: ICU-ecology (Multidrug Resistant Bacteria); ICU-acquired Bacteraemia
Sites: Edegem, Belgium; Ghent, Belgium; Liège, Belgium · 13 sites in all
- Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired InfectionsPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01798537 · 2,400 participants (planned) · Start Jun 2013 · Primary completion Jul 2015
Drug: Neomycin Colistin Nystatin Vancomycin · For: Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
Sites: Haifa, Israel
- Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious VaginitisPivotal-lookingCompleted
Laboratoire Innotech InternationalIndustry
NCT02515656 · 661 participants · Start Sep 2015 · Primary completion Aug 2016
Drug: POLYGYNAX®; GYNODAKTARIN® and 1 more · For: Vaginitis
Sites: Prague, Czechia; Lyon, France; Belgrade, Serbia · 4 sites in all
- A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal CandidiasisPivotal-lookingCompleted
Kamuzu University of Health SciencesAcademic, hospital or other
NCT00128323 · 558 participants · Start Nov 2002
Drug: Gentian violet 1% solution; Gentian violet 0.00165% solution and 1 more · For: Candidiasis, Oral
Sites: Blantyre, Malawi
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06356311 · 473 participants · Start May 3, 2024 · Primary completion Oct 19, 2026
Drug: Sacituzumab tirumotecan; Trifluridine-Tipiracil and 5 more · For: Gastroesophageal Cancer
Sites: Gilbert, Arizona; Los Angeles, California; Orlando, Florida · 168 sites in all
- Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight InfantsPivotal-lookingCompleted
Zekai Tahir Burak Women's Health Research and Education HospitalAcademic, hospital or other
NCT01531192 · 300 participants · Start Jun 2012 · Primary completion Apr 2013
Drug: Nystatin · For: Very Low Birth Weight Infants
Sites: Ankara, Turkey (Türkiye)
- Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral CandidiasisPivotal-lookingCompleted
Pacgen Biopharmaceuticals CorporationIndustry
NCT00659971 · 223 participants · Start Jan 2008 · Primary completion Jun 2008
Drug: PAC113 · For: Oral Candidiasis
Sites: Huntersville, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea2,017
- fatigue1,786
- diarrhoea1,783
- pneumonia1,643
- dyspnoea1,487
- off label use1,475
- vomiting1,390
- drug ineffective1,259
- pain1,225
- death1,152
- pyrexia1,134
- headache1,022
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 282 |
| 2005 | 330 |
| 2006 | 365 |
| 2007 | 339 |
| 2008 | 351 |
| 2009 | 434 |
| 2010 | 529 |
| 2011 | 607 |
| 2012 | 748 |
| 2013 | 697 |
| 2014 | 889 |
| 2015 | 1,327 |
| 2016 | 1,672 |
| 2017 | 1,666 |
| 2018 | 2,073 |
| 2019 | 2,196 |
| 2020 | 2,309 |
| 2021 | 1,793 |
| 2022 | 1,654 |
| 2023 | 1,690 |
| 2024 | 1,632 |
| 2025 | 1,651 |
| 2026 | 1,219 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Candidiasis (oropharyngeal).
Pankhurst CL · BMJ Clin Evid 2013 · Systematic Review
- Candidiasis (oropharyngeal).
Pankhurst CL · BMJ Clin Evid 2009 · Systematic Review
- Candidiasis (oropharyngeal).
Pankhurst CL · BMJ Clin Evid 2012 · Systematic Review
- Candidiasis (vulvovaginal).
Martin Lopez JE · BMJ Clin Evid 2015 · Systematic Review
- Candidiasis (vulvovaginal).
Spence D · BMJ Clin Evid 2007 · Systematic Review
- Candidiasis (vulvovaginal).
Spence D · BMJ Clin Evid 2010 · Systematic Review
Sponsor: Chartwell Molecules
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.